Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives

Dow Jones

07/18

Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives.

The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date.

Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission.

Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000.

"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees," the company said in its filing.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

July 17, 2026 18:14 ET (22:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2652233925"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2652233925\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2652233925?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-18 06:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652233925","market":"fut","top_or_hot":-1,"title":"Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company launched a cash-retention program for executives. \n</p>\n<p>\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n</p>\n<p>\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n</p>\n<p>\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 18:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-18 06:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company launched a cash-retention program for executives. \n</p>\n<p>\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n</p>\n<p>\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n</p>\n<p>\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 18:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2652233925","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652233925","pubTimestamp":1784326440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives.The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date.Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission.Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000.\"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing.Write to Elias Schisgall at elias.schisgall@wsj.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KPTI":"Karyopharm Therapeutics Inc."},"translate_title":"Karyopharm Therapeutics 关于披露高管现金保留计划的幻灯片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":1.5},"content_text":"Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives. \n\n\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n\n\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n\n\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n\n\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2026 18:14 ET (22:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}